TheNFAPost Podcast
1

Bengaluru, NFAPost: Syngene International, an integrated research, development and cGMP manufacturing services company, today announced the expansion of its biomanufacturing capacity.

The company has set up and commissioned a new microbial cGMP facility and has also expanded the capacity of its mammalian cell manufacturing facility to extend end-to-end Chemistry, Manufacturing and Control (CMC) development solutions for its global clients.

Both facilities are located at its Biocon Park campus here. The new microbial facility has two fermenters of 200 litres and 500 litres capacity.

“The use of digitalization and automation tools like electronic quality records and digital signatures will not only help avoid the risk of human errors, but also decrease operational costs and improve time-to-market. Both the facilities are supported by proven processes for efficient, scalable, customized and regulatory-compliant commercial manufacturing,” Syngene International Limited Jonathan Hunt said.

The microbial facility will provide further integration opportunities with the company’s existing discovery and development capabilities and extend service offerings in the space of GMP manufacturing of plasmid DNA and mRNA.

In addition to this, another 2000L single-use bioreactor will be added to the USFDA and EMA compliant mammalian manufacturing facility. This is expected to strengthen Syngene’s service offerings for commercial supply.

The expansion is building on Syngene’s existing biopharmaceuticals manufacturing capabilities and is aligned with its strategic focus on biologics as one of its future growth drivers.

The global biologics market size is expected to reach $749.62 billion in 2028 at a CAGR of 10.8% from 2021. The cancer segment accounted for the largest revenue share in the global biologics market in 2020, due to increasing prevalence of the disease worldwide.

In the last decade, the focus of new investments in the biologics sector has shifted toward mammalian cell culture due to the dominance of monoclonal antibodies. This has resulted in the need for microbial service providers worldwide.

Previous articleMicrosoft Protests US Govt’s Decision To Award NSA Cloud Contract To AWS
Next articleMETRO Cash & Carry India Opens Its 30th Store

LEAVE A REPLY

Please enter your comment!
Please enter your name here